The purposes of this study were to investigate firstly, the ankle joint stiffness during the eccentric phase in rebound jumps, and secondly, the effect of ankle joint stiffness during the eccentric phase on ankle joint torque at midpoint. Nine active males executed rebound drop jumps from a height of 30 cm (RDJ30) and 50 cm (RDJ50), and 5-repetition rebound jumps (5RJ). Force plate data, limb position and electromyogram (EMG) of the medial head of gastrocnemius (GAS), soleus (SOL), and tibialis anterior (TA) muscles were recorded simultaneously during all jumps. When compared with RDJ30 and RDJ50, 5RJ displayed significantly higher jumping height, ankle joint torque at midpoint, ankle joint stiffness during the eccentric phase, and integrated EMG (IEMG) of GAS and SOL. Furthermore, 5RJ displayed significantly lower contact time and IEMG of TA than RDJ30 and RDJ50 did. The ankle joint torque at midpoint showed a significant positive correlation with jumping height but a significant negative correlation with contact time in rebound jumps. There was a significant positive correlation between the ankle joint stiffness during the eccentric phase and ankle joint torque at midpoint in rebound jumps. These results suggested that for the rebound jumps to be effective, it may be important to enhance the ankle joint torque at midpoint by greater ankle joint stiffness during the eccentric phase. These results also suggested that compared to 5RJ, RDJ30 and RDJ50 may reduce ankle joint stiffness in order to protect the tendomuscular system from the stretch load. However, ankle joint stiffness is possibly increased in 5RJ because the restraint to defend the tendomuscular system is reduced by prediction or adaptation to the stretch load because it is a continuous jump.

It has been shown that aerobic exercise improves atopic dermatitis (AD), although the mechanism is not clear. Here, we propose a hypothesis that moderate‐intensity aerobic exercise improves AD in a mouse model through modulating allergic inflammation. The DNCB‐treated mouse model for eczema was divided into 3 groups: (a) not subjected to aerobic exercise, (b) subjected to continuous aerobic exercise and (c) subjected to accumulated aerobic exercise. After given exercise using a treadmill device either 30 min/d or 10 min × 3/day at a speed of 16 m/min, for 9 days, respectively, dermatitis symptom score, thickness of epidermis/dermis and eosinophil infiltration were decreased in the 2 exercise groups compared to the sedentary living group. The serum levels of IgE, MCP‐1 and MDC showed a significant decrease both in the continuous or accumulated exercise groups. Moderate‐intensity aerobic exercise ameliorates dermatitis symptoms through immune modulation in the DNCB‐treated mouse model for eczema.

Background: This study aimed to compare the effects of applying a vibrating foam roller before resistance exercise versus after resistance exercise on changes in serum muscle damage markers, muscle stiffness, and range of motion. This study also aimed to provide foundational data for optimizing the timing of vibrating foam roller application to enhance recovery after resistance exercise in practical settings.Methods: Twelve healthy adult males were recruited as participants. Each participant was subjected to three interventions in a random order with a washout period of at least 5 days: vibration foam rolling before resistance exercise, vibration foam rolling after resistance exercise, and resistance exercise without vibration foam rolling. Blood creatine kinase, knee flexion range of motion, and muscle stiffness were measured before, immediately after, 24 hours after, and 48 hours after exercise and foam rolling protocols.Results: Creatine kinase levels in vibration foam rolling after resistance exercise were significantly lower than those in vibration foam rolling before resistance exercise at 24 and 48 hours post-exercise. Muscle stiffness was significantly lower immediately and 24 hours post-exercise in vibration foam rolling after resistance exercise than in vibration foam rolling before resistance exercise and resistance exercise without vibration foam rolling. Knee flexion range of motion was significantly lower in resistance exercise without vibration foam rolling than in vibration foam rolling after resistance exercise at 24 and 48 hours post-exercise.Conclusions: The application of vibration foam rolling after resistance exercise was more effective than that before exercise in decreasing muscle damage markers, reducing muscle stiffness, and improving the range of motion.

7721 Background: Etoposide/cisplatin (EP) is the most widely used regimen resulting in a median survival of 8–10 mos and 17–20 mos respectively for patients (pts) with extensive-disease (ED) and limited-disease (LD). Encouraged by a phase III trial result that showed better survival outcome after Irinotecan/cisplatin (IP) combination as compared with EP, we previously reported promising activity of IP regimen for LD-SCLC and also for ED-SCLC. To further evaluate the role of IP in SCLC pts, we conducted two additional phase II studies. Methods: Between May 2003 and June 2006, a total of 196 SCLC pts (ED: 120, LD: 76) were enrolled in two separate trials. All pts were chemo-naive and ECOG PS of 0–2. Pts with ED-SCLC received irinotecan 60 mg/m² intravenously (IV) and cisplatin 30 mg/m² IV on days 1 and 8 every 21 days for 8 cycles followed by 6 cycles of irinotecan maintenance or observation. Treatment for LD-SCLC consisted of two 28-day cycles of cisplatin 30 mg/m² IV on days 1 and 8 plus irinotecan 60 mg/m² IV on days 1, 8, and 15, followed by two 21-day cycles of cisplatin 60 mg/m² IV on day 1, plus etoposide 100 mg/m² IV on days 1 to 3 with concurrent twice-daily thoracic radiation of total 45 Gy. Hoping to modify the treatment-related toxicity, 36 pts were given epoietin and 20 were given amifostine while 15 received neither during the concurrent chemo-radiation therapy. Results: For ED- SCLC, overall response rate was 92.6% with CR rate of 11.1%. The median survival was 13.8 mos (95% CI, 12.2 to15.3) with 1-and 2-year survival rates of 58.6% and 18.9%. The median progression-free survival (PFS) was 7.3 mos with 1-and 2-year PFS rates of 18.1% and 5.4%. Irinotecan maintenance did not affect the outcome, however. For LD-SCLC, the response rate was 97.1% with CR rate of 44.9%. The median survival was 24.9 mos (95% CI, 18.5 to 31.3) with 1-and 2-year survival rates of 75.2% and 51.4%. The median PFS was 11.0 mos (95% CI, 7.8–14.2) with 1-year PFS rates of 46.8%. The most common toxicity associated with IP treatment was grade 3 or 4 neutropenia (64.6% for ED, 45.3% for LD). Grade 3 diarrhea was developed in 12.4% for ED and 4% for LD pts. Conclusion: Significant antitumor activity of IP chemotherapy as shown suggests further progress in SCLC therapy. No significant financial relationships to disclose.